Halaven (eribulin mesylate) / Eisai 
Welcome,         Profile    Billing    Logout  
 71 Diseases   105 Trials   105 Trials   2830 News 


«12345678910111213...3738»
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Hall A; Poster Bd #: 303) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_2129;    
    P2
    Although manageable, neutropenia emerged as a notable adverse effect. These findings underscore the potential of this combination as a therapeutic strategy for advanced solid tumors, warranting further clinical investigation.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, ML210 / University of Sydney
    Journal:  Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma. (Pubmed Central) -  Apr 22, 2024   
    Taken together, our findings show firstly that eribulin triggers ferroptosis in OCCC and this effect occurs via the suppression of the Nrf2-HO-1 signaling pathway, SOD activity and the promotion of lipid peroxidation. These findings suggest that eribulin-induced ferroptosis is associated with its anti-tumor effect and also could be a potential therapeutic target in OCCC.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal, Metastases:  Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells. (Pubmed Central) -  Mar 31, 2024   
    Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.
  • ||||||||||  Trodelvy (sacituzumab govitecan-hziy) / Gilead
    Review, Journal, Metastases:  Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer. (Pubmed Central) -  Mar 26, 2024   
    Sacituzumab govitecan demonstrated an overall benefit in terms of health-related quality of life. Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer.
  • ||||||||||  ELVN-002 / Enliven Therap
    Enrollment open, Metastases:  ELVN-002-003: ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer (clinicaltrials.gov) -  Mar 26, 2024   
    P1,  N=255, Recruiting, 
    Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer. Not yet recruiting --> Recruiting
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) -  Mar 25, 2024   
    Not yet recruiting --> Recruiting A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
  • ||||||||||  TQB2930 / Sino Biopharm
    Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) -  Mar 12, 2024   
    P1/2,  N=154, Recruiting, 
    Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted. N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
  • ||||||||||  Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) -  Mar 12, 2024   
    P2,  N=30, Recruiting, 
    N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026 Trial completion date: May 2025 --> Aug 2027 | Trial primary completion date: Nov 2023 --> Jun 2027
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Mechanistic evaluations of the immunological and cell biological effects that distinguish eribulin from other microtubule-targeted chemotherapeutics (Section 2) -  Mar 5, 2024 - Abstract #AACR2024AACR_8205;    
    Both genetic and pharmacological inhibitors of GEF-H1 were utilized to interrogate the relationship between eribulin-mediated microtubule destabilization and TBK1/IRF3-dependent immunological activation as well as the formation of RhoA-dependent focal adhesions and reversal of EMT-associated phenotypes. Together, our data provide a mechanistic rationale for unique effects of eribulin as compared to other classes of MTAs that could inform on the use of these widely used, but mechanistically underappreciated drugs in a more personalized manner and inform on their rational combination with targeted agents, including immunotherapy.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Analysis of the effect of eribulin on tumor immunity against triple-negative breast cancer (Section 39) -  Mar 5, 2024 - Abstract #AACR2024AACR_6520;    
    Our findings suggest that eribulin can facilitate the proliferation of CD8+ T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells in vitro. Further analysis of the effects of eribulin on TNBC cells and immune cells in vivo is required, and we continue to analyze immunomodulation in patients treated with eribulin.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Determining the role of septin expression in response of breast cancer patients to microtubule targeted chemotherapy (Section 45) -  Mar 5, 2024 - Abstract #AACR2024AACR_6451;    
    Drugs that disrupt the microtubule cytoskeleton, including both microtubule stabilizing taxanes and destabilizers like eribulin, are regularly used in the treatment of metastatic breast cancer...These data were used to support an ongoing prospective study to determine effect of septin expression on response to taxane chemotherapy in the neoadjuvant setting and determine the effect of taxane treatment on septin expression by comparing samples pre and post treatment. Together this work supports our overall goal of identifying predictive biomarkers to facilitate the use of microtubule targeted chemotherapy in a more personalized manner.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
    Sensitization to chemo-immunotherapy by targeting TGF-? in preclinical triple negative breast cancer models (Section 47) -  Mar 5, 2024 - Abstract #AACR2024AACR_2435;    
    The IMpassion 130 trial demonstrated the efficacy of nab-paclitaxel and atezolizumab (anti-PD-L1) in PD-L1+ patients, but unfortunately, IMpassion 131 with paclitaxel did not replicate these results...Optimizing chemo-immunotherapy combinations is a major challenge in the management of TNBC.The initial aim of this project was to evaluate the immune effects of an experimental chemotherapy doublet, based on two drugs used in mTNBC: cisplatin (CDDP) and eribulin...The results show that inhibition of TGF-?, combined with chemo-immunotherapy in the 4T1 model, leads to a reduction in tumor immunosuppression and intratumoral fibrosis, as well as an increase in CTL infiltration and cytotoxicity, enabling tumor sensitization.Overall, this project highlights the benefits of using an experimental doublet of CDDP and eribulin-based chemotherapies. This project demonstrates that management of chemo-induced immunosuppression mechanisms is necessary to overcome tumor resistance to immunotherapy.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
    Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker:  A Case of Triple Negative Breast Cancer with Successful Control of Recurrent Disease Activity for More than Ten Years (Pubmed Central) -  Feb 6, 2024   
    Applicable regimens of drug therapy are still available at present and drug therapy has been continued based on a discussion and mutual understanding of the adverse reactions, etc. with the patient. Few reports have been published concerning long-term survivors among TN breast cancer cases.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, eribulin liposomal (E7389-LF) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
    P2 data, Journal, Combination therapy, PD(L)-1 Biomarker:  Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. (Pubmed Central) -  Jan 31, 2024   
    If the primary endpoint is met, it is our hope that eribulin will be regarded as a standard medication for patients with advanced EMPD. Promising antitumor activity was observed with E7389-LF in combination with nivolumab in patients with GC, and no new safety signals were observed, compared with either monotherapy.
  • ||||||||||  Journal, Adverse events, Real-world evidence, Real-world:  Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021. (Pubmed Central) -  Jan 31, 2024   
    We also found some drugs without DILD in the labels, such as amiodarone, temsirolimus, and ursodiol...For example, the United States and France reported more cardiovascular agents, whereas Canada reported more antirheumatic agents. We found the top drugs and drug classes that were associated with DILD in the FAERS, which provides a real-world window for different ages, sexes, and countries to formulate precise pharmacovigilance policies.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Journal, Metastases:  Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood?based parameters and ratio. (Pubmed Central) -  Jan 26, 2024   
    Multivariate analysis revealed low ALBI grade (P<0.001), high Hb (P<0.01) and low PLR (P<0.05) as independent factors of longer OS after eribulin administration. Low PLR, anemia and liver dysfunction might be factors associated with prolonged OS in patients with metastatic BC on eribulin therapy, which could be clinically useful, as their evaluation requires neither new equipment nor invasive testing.
  • ||||||||||  Enrollment change, Trial withdrawal:  SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) -  Jan 23, 2024   
    P1,  N=0, Withdrawn, 
    Low PLR, anemia and liver dysfunction might be factors associated with prolonged OS in patients with metastatic BC on eribulin therapy, which could be clinically useful, as their evaluation requires neither new equipment nor invasive testing. N=25 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Trastuzumab deruxtecan (T-DXd) versus treatment of physician () -  Jan 22, 2024 - Abstract #YIR2024YIR_128;    
    P1, P3
    557 pts with centrally confirmed HER2-low mBC were randomly assigned 2:1 to T-DXd 5.4 mg/kg or TPC (capecitabine, eribulin, gemcitabine, paclitaxel, or nab-paclitaxel). DESTINY-Breast04 is the first phase 3 trial of a HER2-directed therapy in pts with HER2-low mBC to show a statistically significant and clinically meaningful benefit in PFS and OS compared to standard-of-care treatment, regardless of HR status, with a generally manageable safety profile.